<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ANG</journal-id>
<journal-id journal-id-type="hwp">spang</journal-id>
<journal-id journal-id-type="nlm-ta">Angiology</journal-id>
<journal-title>Angiology</journal-title>
<issn pub-type="ppub">0003-3197</issn>
<issn pub-type="epub">1940-1574</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0003319712458145</article-id>
<article-id pub-id-type="publisher-id">10.1177_0003319712458145</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Coronary Heart Diseases</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Impact of Chronic Obstructive Pulmonary Diseases on Outcomes and Hospital Days After Percutaneous Coronary Intervention</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Jian Wei</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319712458145">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Zhou</surname>
<given-names>Yu Jie</given-names>
</name>
<degrees>MD, PhD, FACC</degrees>
<xref ref-type="aff" rid="aff1-0003319712458145">1</xref>
<xref ref-type="corresp" rid="corresp1-0003319712458145"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yang</surname>
<given-names>Qing</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319712458145">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yang</surname>
<given-names>Shi Wei</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319712458145">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nie</surname>
<given-names>Bin</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319712458145">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Xu</surname>
<given-names>Xiao Han</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319712458145">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0003319712458145">
<label>1</label>Department of Cardiology, Anzhen Hospital, Capital Medical University, Beijing, China</aff>
<author-notes>
<corresp id="corresp1-0003319712458145">Yu Jie Zhou, Department of Cardiology, Anzhen Hospital, Capital Medical University, Beijing 100029, China. Email: <email>azzyj12@163.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2013</year>
</pub-date>
<volume>64</volume>
<issue>6</issue>
<fpage>430</fpage>
<lpage>434</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Chronic obstructive pulmonary disease (COPD) is common in patients undergoing percutaneous coronary intervention (PCI), but the impact of COPD on outcomes after PCI has received limited attention. Consecutive patients with coronary heart disease (n = 5155) undergoing PCI were enrolled in this study; 645 patients (73% men) aged 68.4 ± 13.2 years had COPD and 4510 patients (71% men) aged 64.7 ± 12.1 years did not. During the in-hospital period after PCI, the patients with COPD experienced a significantly higher incidence of angina (<italic>P</italic> &lt; .001), arrhythmias (<italic>P</italic> &lt; .001), and composite major adverse cardiac events (MACEs; <italic>P</italic> &lt; .001) and longer hospital stay (<italic>P</italic> &lt; .001) than those without COPD. Additionally, severity of COPD (measured by pulmonary function tests) was associated with increased composite MACE (<italic>P</italic> &lt; .001) and hospital stay (<italic>P</italic> &lt; .001) after PCI. In conclusion, COPD is associated with significantly increased composite MACE and hospital stay in patients after PCI. Increasing severity of COPD is associated with increased composite MACE and hospital stay after PCI.</p>
</abstract>
<kwd-group>
<kwd>chronic obstructive pulmonary disease</kwd>
<kwd>hospital stay</kwd>
<kwd>percutaneous coronary intervention</kwd>
<kwd>major adverse cardiac events</kwd>
<kwd>pulmonary function test</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0003319712458145">
<title>Introduction</title>
<p>Chronic obstructive pulmonary disease (COPD) is highly prevalent among patients with coronary heart disease (CHD) because both diseases share a key common risk factor—smoking. Chronic obstructive pulmonary disease is associated with increased overall and cardiovascular mortality both in the general population<sup>
<xref ref-type="bibr" rid="bibr1-0003319712458145">1</xref>
<xref ref-type="bibr" rid="bibr2-0003319712458145"/>
<xref ref-type="bibr" rid="bibr3-0003319712458145"/>–<xref ref-type="bibr" rid="bibr4-0003319712458145">4</xref>
</sup> and in patients with CHD undergoing coronary bypass grafting.<sup>
<xref ref-type="bibr" rid="bibr5-0003319712458145">5</xref>
<xref ref-type="bibr" rid="bibr6-0003319712458145"/>–<xref ref-type="bibr" rid="bibr7-0003319712458145">7</xref>
</sup> However, the impact of COPD on outcomes and hospital stay after percutaneous coronary intervention (PCI) has received limited attention.</p>
</sec>
<sec id="section2-0003319712458145" sec-type="materials|methods">
<title>Materials and Methods</title>
<p>We carried out a retrospective analysis of prospectively acquired data from patients in our hospital that includes clinical, laboratory, echocardiography angiographic, and procedural data. In-hospital adverse cardiac events after coronary interventions and hospital stay were recorded. All adverse events were confirmed by reviewing the medical records. All patients who underwent PCI between January 2006 and January 2011 were identified.</p>
<p>Patient medical records were searched for the diagnosis of COPD. To define categories of COPD severity, we used pulmonary function tests (PFTs) performed at our institution and standard cutoff values from accepted guidelines.<sup>
<xref ref-type="bibr" rid="bibr8-0003319712458145">8</xref>
</sup>
</p>
<p>
<table-wrap id="table4-0003319712458145" position="float">
<graphic alternate-form-of="table4-0003319712458145" xlink:href="10.1177_0003319712458145-table4.tif"/>
<table>
<thead>
<tr>
<th colspan="3">Classification of Severity of Airflow Limitation in COPD (Based on Postbronchodilator FEV1)</th>
</tr>
<tr>
<th colspan="3">In patients with FEV1/FVC &lt;0.70</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group 1</td>
<td>Mild</td>
<td>FEV1 ≥80% predicted</td>
</tr>
<tr>
<td>Group 2</td>
<td>Moderate</td>
<td>50% ≤FEV1 &lt;80% predicted</td>
</tr>
<tr>
<td>Group 3</td>
<td>Severe</td>
<td>30% ≤FEV1 &lt;50% predicted</td>
</tr>
<tr>
<td>Group 4</td>
<td>Very severe</td>
<td>FEV1 &lt;30% predicted or the presence of respiratory failure or clinical signs of right heart failure</td>
</tr>
</tbody>
</table>
</table-wrap>
</p>
<sec id="section3-0003319712458145">
<title>End Point Definitions</title>
<p>The primary outcomes were all-cause mortality, nonfatal myocardial infarction (MI), life-threatening cardiac arrhythmias with a need for resuscitation or pacemaker implantation, angina with electrocardiogram changes, repeat target lesion revascularization by PCI, or coronary artery bypass graft in hospital.</p>
</sec>
<sec id="section4-0003319712458145">
<title>Statistical Analysis</title>
<p>Categorical data are presented as frequencies (percentages); continuous data are presented as mean value ± standard deviation. We used the χ<sup>
<xref ref-type="bibr" rid="bibr2-0003319712458145">2</xref>
</sup> test to compare the categorical variables and the 2-sample <italic>t</italic> test for continuous variables. Statistically significant factors were examined using multivariate logistic regression. A <italic>P</italic> &lt; .05 (2-sided) was considered significant. Data were analyzed with SPSS 13.0 (Chicago, Illinois).</p>
</sec>
</sec>
<sec id="section5-0003319712458145">
<title>Results</title>
<sec id="section6-0003319712458145">
<title>Baseline Patient Characteristics</title>
<p>We enrolled 5155 patients who underwent PCI at our institution between January 2006 and January 2011. Of this sample, 645 patients met the definition of COPD and 4510 did not. As shown in <xref ref-type="table" rid="table1-0003319712458145">Table 1</xref>, patients with COPD were older, had a greater prevalence of hypertension, and were more likely to be current or past smokers. Prevalence of serious cardiovascular comorbidity was higher in the patients with COPD, including a history of MI, heart failure, or cerebral ischemia. Prevalence of baseline C-reactive protein (CRP) &gt;5 mg/L and white blood cell (WBC) count abnormal was higher in the patients with COPD. Sex, serum creatinine level, and contrast-induced nephropathy<sup>
<xref ref-type="bibr" rid="bibr9-0003319712458145">9</xref>,<xref ref-type="bibr" rid="bibr10-0003319712458145">10</xref>
</sup> were similar in both the groups. Patients without COPD had a higher mean ejection fraction. Both groups had similar procedural success rates as well as similar rates of emergency PCIs, postprocedural flows, and number of stents used.</p>
<table-wrap id="table1-0003319712458145" position="float">
<label>Table 1.</label>
<caption>
<p>Patient Characteristics.<sup>a</sup>
</p>
</caption>
<graphic alternate-form-of="table1-0003319712458145" xlink:href="10.1177_0003319712458145-table1.tif"/>
<table>
<thead>
<tr>
<th>Characteristic</th>
<th>No COPD (n = 4510)</th>
<th>COPD (n = 645)</th>
<th>P </th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>64.7 ± 12.1</td>
<td>68.4 ± 13.2</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Male sex</td>
<td>3202 (71%)</td>
<td>471 (73%)</td>
<td>.29</td>
</tr>
<tr>
<td>BMI, kg/m2</td>
<td>25.2 ± 4.6</td>
<td>25.1 ± 4.7</td>
<td>.61</td>
</tr>
<tr>
<td>Baseline CRP &gt;5 mg/L</td>
<td>680 (15%)</td>
<td>247 (38%)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Baseline WBC count abnormal</td>
<td>453 (10%)</td>
<td>154 (24%)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>2841 (63%)</td>
<td>419 (65%)</td>
<td>.33</td>
</tr>
<tr>
<td>Hypertension</td>
<td>3202 (71%)</td>
<td>484 (75%)</td>
<td>.03</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>992 (22%)</td>
<td>161 (25%)</td>
<td>.0909</td>
</tr>
<tr>
<td>History of CABG</td>
<td>45 (1%)</td>
<td>10 (1.55%)</td>
<td>.20</td>
</tr>
<tr>
<td>History of MI</td>
<td>1353 (30%)</td>
<td>264 (41%)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>History of cerebral vascular ischemia</td>
<td>338 (7.5%)</td>
<td>105 (16%)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Current smoking</td>
<td>590 (29%)</td>
<td>245 (38%)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Any history of smoking</td>
<td>2571 (57%)</td>
<td>477 (74%)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Creatinine preprocedure, mg/dL</td>
<td>1.2 ± 4.8</td>
<td>1.3 ± 5.1</td>
<td>.64</td>
</tr>
<tr>
<td>Contrast-induced nephropathy</td>
<td>203 (4.5%)</td>
<td>32 (4.96%)</td>
<td>.60</td>
</tr>
<tr>
<td>Ejection fraction, %</td>
<td>54 ± 15</td>
<td>51 ± 15</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Use of β-blockers</td>
<td>3150 (69.8%)</td>
<td>315 (48.8%)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Emergency PCI</td>
<td>375 (8.3%)</td>
<td>57 (8.8%)</td>
<td>.65</td>
</tr>
<tr>
<td>Procedural success</td>
<td>4375 (97%)</td>
<td>620 (96%)</td>
<td>.23</td>
</tr>
<tr>
<td>Drug-eluting stent use</td>
<td>4415 (98%)</td>
<td>625 (97%)</td>
<td>.11</td>
</tr>
<tr>
<td>Bare-metal stent use</td>
<td>95 (2%)</td>
<td>20 (3%)</td>
<td>.11</td>
</tr>
<tr>
<td>Number of stents placed</td>
<td>2.5 ± 1.2</td>
<td>2.6 ± 1.3</td>
<td>.07</td>
</tr>
<tr>
<td>Bifurcation lesion</td>
<td>721 (16%)</td>
<td>97 (15%)</td>
<td>.54</td>
</tr>
<tr>
<td>TIMI-3 flow postprocedure</td>
<td>4375 (97%)</td>
<td>620 (96%)</td>
<td>.23</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0003319712458145">
<p>Abbreviations: BMI, body mass index; CRP, C-reactive protein; WBC, white blood cells; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; MI, myocardial infarction; PCI, percutaneous coronary intervention.</p>
</fn>
<fn id="table-fn2-0003319712458145">
<p>
<sup>a</sup> Data are presented as mean ± SD or n (%).</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section7-0003319712458145">
<title>Primary Outcomes and Hospital Days</title>
<p>The primary outcomes and hospital days for the COPD and non-COPD groups are shown in <xref ref-type="table" rid="table2-0003319712458145">Table 2</xref>. Univariate analysis revealed that COPD was associated with higher occurrence of arrhythmias (<italic>P</italic> &lt; .001) and angina (<italic>P</italic> &lt; .001). Composite major adverse cardiac events (MACEs) occurred in 8.6% of patients without COPD and in 19.4% of patients with COPD (<italic>P</italic> &lt; .001). Patients with COPD had a longer hospital stay compared with patients without COPD (<italic>P</italic> &lt; .001). A multivariable model adjusting for age, baseline CRP &gt;5 mg/L, abnormal baseline WBC count, the use of β-blockers, history of current smoking, and low left ventricular ejection fraction was constructed. After adjustment for these baseline differences, COPD remained an independent risk factor for occurrence of angina (odds ratio [OR], 1.76; 95% confidence interval [CI], 1.52-2.01; adjusted <italic>P</italic> &lt; .001), arrhythmias (OR, 1.82; 95% CI, 1.58-2.06; adjusted <italic>P</italic> &lt; .001), composite MACE (OR, 1.67; 95% CI, 1.41-1.94; adjusted <italic>P</italic> &lt; .001), and hospital stay (OR, 1.87; 95% CI, 1.64-2.10; adjusted <italic>P</italic> &lt; .001).</p>
<table-wrap id="table2-0003319712458145" position="float">
<label>Table 2.</label>
<caption>
<p>Major Adverse Cardiac Events and Hospital Days.<sup>a</sup>
</p>
</caption>
<graphic alternate-form-of="table2-0003319712458145" xlink:href="10.1177_0003319712458145-table2.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th>COPD</th>
<th>Non-COPD</th>
<th>
<italic>P</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>Death</td>
<td>3 (0.31)</td>
<td>11(0.24)</td>
<td>.91</td>
</tr>
<tr>
<td>Nonfatal MI</td>
<td>15 (2.3)</td>
<td>82 (1.8)</td>
<td>.37</td>
</tr>
<tr>
<td>Angina</td>
<td>55 (8.5)</td>
<td>148 (3.3)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Arrhythmias</td>
<td>40 (6.2) </td>
<td>101 (2.2)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Revascularization</td>
<td>12 (1.86)</td>
<td>47 (1.04)</td>
<td>.07</td>
</tr>
<tr>
<td>Composite MACE</td>
<td>125 (19.4)</td>
<td>389 (8.6)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Hospital days</td>
<td>7.3 ± 2.1</td>
<td>5.2 ± 1.6</td>
<td>&lt;.001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0003319712458145">
<p>Abbreviations: MACE, major adverse cardiac events; MI, myocardial infarction.</p>
</fn>
<fn id="table-fn4-0003319712458145">
<p>
<sup>a</sup> Data are presented as mean ± SD or n (%). </p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section8-0003319712458145">
<title>Severity and Outcomes of COPD</title>
<p>Results of PFT were available for 458 (71%) patients with COPD. Of these, 41 (9%) had very severe COPD, 105 (23%) had severe COPD, 179 (39%) had moderate COPD, and 87 (19%) had mild COPD. In addition, 46 (10%) patients had a forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) &gt;0.70 and received a clinical diagnosis of COPD, in whom the PFT showed an FEV1/FVC &gt;0.70, but they had a mean FEV1 of 72% ± 15% predicted. For the purposes of further analysis, we combined the mild, moderate, and FEV 1/FVC &gt;0.70 COPD groups into one category, and combined the severe and very severe COPD groups into another category. As shown in <xref ref-type="table" rid="table3-0003319712458145">Table 3</xref>, composite MACE was significantly higher with increasing severity of COPD, and hospital stay was longer with increasing severity of COPD.</p>
<table-wrap id="table3-0003319712458145" position="float">
<label>Table 3.</label>
<caption>
<p>Subgroup Composite MACE and Hospital Days.<sup>a</sup>
</p>
</caption>
<graphic alternate-form-of="table3-0003319712458145" xlink:href="10.1177_0003319712458145-table3.tif"/>
<table>
<thead>
<tr>
<th> </th>
<th>Non-COPD, n = 4510</th>
<th>Mild, Moderate, and FEV1/FVC &gt;0.70 COPD, n = 312</th>
<th>Severe and Very Severe COPD, n = 146</th>
<th>
<italic>P</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>Composite MACE</td>
<td>389 (8.6)</td>
<td>47 (15.1)</td>
<td>50 (34.2)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Hospital days</td>
<td>5.2 ± 1.6</td>
<td>6.1 ± 2.3</td>
<td>8.3 ± 2.5</td>
<td>&lt;.001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-0003319712458145">
<p>Abbreviation: MACE, major adverse cardiac events.</p>
</fn>
<fn id="table-fn6-0003319712458145">
<p>
<sup>a</sup> Data are presented as mean ± SD or n (%).</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="section9-0003319712458145">
<title>Discussion</title>
<p>In 2020, COPD is projected to rank fifth worldwide in terms of burden of disease, according to the World Bank/World Health Organization.<sup>
<xref ref-type="bibr" rid="bibr11-0003319712458145">11</xref>
</sup> Our main finding is that patients with COPD have a higher composite MACE and hospital stay after PCI. These patients with COPD are at an increased risk of adverse cardiovascular outcomes, such angina and arrhythmia after PCI in hospital, and the severity of COPD is correlated with composite MACE and hospital stay after PCI. These findings suggest that screening for COPD and establishing the severity of this disease could help in risk stratification to determine the intensity of follow-up and treatment.</p>
<p>The association between COPD and coronary artery disease (CAD) is known, and cigarette smoking is clearly the primary determinant of COPD mortality.<sup>
<xref ref-type="bibr" rid="bibr12-0003319712458145">12</xref>
</sup> Decreased pulmonary function is an independent risk factor for CHD mortality.<sup>
<xref ref-type="bibr" rid="bibr12-0003319712458145">12</xref>
</sup> However, data on patients with COPD undergoing PCI are limited. Some studies<sup>
<xref ref-type="bibr" rid="bibr13-0003319712458145">13</xref>
<xref ref-type="bibr" rid="bibr14-0003319712458145"/>–<xref ref-type="bibr" rid="bibr15-0003319712458145">15</xref>
</sup> that focused on mortality in patients undergoing PCI suggested worse prognosis in those with COPD in follow-up, but the in-hospital mortality and hospital stay could not be considered, and cardiovascular outcomes such as recurrent arrhythmia and hospital days were not studied. Our study involved 5155 patients who underwent PCI at a single academic institution for which diagnosis of COPD was confirmed by review of medical records and available PFT results. Due to the short period of observation, the results of this study did not indicate worse all-cause mortality in patients with COPD after PCI in hospital. The well-recognized link between COPD and CHD has been considered to be cigarette smoking, but recent evidence points to additional mechanisms. Patients with COPD have a systemic inflammatory response, including CRP elevation during chronic disease and acute exacerbations.<sup>
<xref ref-type="bibr" rid="bibr16-0003319712458145">16</xref>
</sup> Altered neurohumoral activation in COPD also has been well described<sup>
<xref ref-type="bibr" rid="bibr17-0003319712458145">17</xref>
</sup>; they were shown to have increased peripheral sympathetic activation,<sup>
<xref ref-type="bibr" rid="bibr18-0003319712458145">18</xref>
</sup> depressed heart rate variability,<sup>
<xref ref-type="bibr" rid="bibr16-0003319712458145">16</xref>
</sup> and increased baroreflex sensitivity.<sup>
<xref ref-type="bibr" rid="bibr19-0003319712458145">19</xref>,<xref ref-type="bibr" rid="bibr20-0003319712458145">20</xref>
</sup> Furthermore, the prevalence and intensity of obstructive sleep apnea is high in patients with COPD.<sup>
<xref ref-type="bibr" rid="bibr21-0003319712458145">21</xref>
</sup> Obstructive sleep apnea is associated with metabolic syndrome, which increases the risk of cardiovascular diseases.<sup>
<xref ref-type="bibr" rid="bibr22-0003319712458145">22</xref>
</sup> Chronic obstructive pulmonary disease could contribute to CAD through additional pathologic mechanisms, such as increased pulmonary hypertension, right-sided heart failure, or other recently identified mechanisms (impaired flow-mediated dilatation,<sup>
<xref ref-type="bibr" rid="bibr23-0003319712458145">23</xref>
</sup> increased arterial stiffness,<sup>
<xref ref-type="bibr" rid="bibr24-0003319712458145">24</xref>
</sup> and endothelial dysfunction<sup>
<xref ref-type="bibr" rid="bibr25-0003319712458145">25</xref>
</sup>).</p>
<p>Moreover, systemic inflammation has been suggested to be involved in the pathogenesis of COPD and metabolic syndrome, the presence of metabolic syndrome is frequent in patients with COPD.<sup>
<xref ref-type="bibr" rid="bibr26-0003319712458145">26</xref>,<xref ref-type="bibr" rid="bibr27-0003319712458145">27</xref>
</sup> Chronic obstructive pulmonary disease is a very strong predictor of hemodynamic compromise resulting in death or cardiogenic shock in patients presenting with ST-elevation MI; hemodynamic and pulmonary consequences of COPD decrease the capacity of the circulatory system to adjust to the effects of acute MI.<sup>
<xref ref-type="bibr" rid="bibr28-0003319712458145">28</xref>
</sup>
</p>
<p>Whether the severity of COPD can alter PCI outcomes has only been evaluated in one study. This study showed that there was a clearly increased mortality rate with each additional level of COPD severity,<sup>
<xref ref-type="bibr" rid="bibr15-0003319712458145">15</xref>
</sup> namely patients with mild or moderate COPD did better than those with severe COPD who, in turn, did better than those with very severe COPD. Patients without COPD had better survival than those with any level of COPD. Our results focussed on composite in-hospital MACE and hospital stay; there was a clearly increased composite MACE rate and hospital stay with each additional level of COPD severity.</p>
<p>When comparing the baseline characteristics of patients with COPD with those without COPD (<xref ref-type="table" rid="table1-0003319712458145">Table 1</xref>), our results were consistent with previous studies<sup>
<xref ref-type="bibr" rid="bibr13-0003319712458145">13</xref>,<xref ref-type="bibr" rid="bibr15-0003319712458145">15</xref>
</sup> and showed that patients with COPD were older and had an increased prevalence of cardiovascular risk factors. Various manifestations of cardiovascular diseases were also more prevalent in the personal history of patients with COPD, including MI, heart failure, and cerebral ischemia. This is consistent with the reports from large population-based studies.<sup>
<xref ref-type="bibr" rid="bibr29-0003319712458145">29</xref>,<xref ref-type="bibr" rid="bibr30-0003319712458145">30</xref>
</sup> We found that patients with COPD had an increased prevalence in baseline CRP &gt;5 mg/L and raised baseline WBC count. Inflammatory processes in the vessel wall are associated with the progression of atherosclerosis and MI, high serum levels of CRP have been linked to an increased risk of ischemic events after PCI, a high serum CRP level before PCI is independently associated with a higher risk of long-term death or MI.<sup>
<xref ref-type="bibr" rid="bibr31-0003319712458145">31</xref>
</sup> Some research showed both elevated and low WBC counts are associated with increased mortality and MACE at 1 year following PCI with drug eluting stent (DES), and WBC count is an independent predictor of survival in patients who undergo PCI with DES implantation.<sup>
<xref ref-type="bibr" rid="bibr32-0003319712458145">32</xref>
</sup> We found that patients with COPD had an increased prevalence of baseline CRP &gt;5 mg/L and abnormal baseline WBC count. It is likely that these baseline differences were responsible for at least some of the detrimental effect on the outcomes of patients with COPD. The data from the TRatamiento de la Enfermedad Coronaria en Espana—Treatment of Coronary Heart Disease (TRECE) study in Spain<sup>
<xref ref-type="bibr" rid="bibr33-0003319712458145">33</xref>
</sup> have enabled us to identify that atrial fibrillation, COPD, and comorbid conditions are the main limiting factors for the therapeutic implementation of optimal medical therapy, severe forms of COPD are a relative contraindication to the use of β-blockers, though these drugs reduce the incidence of angina and arrhythmias and the number of readmissions. We conclude that COPD was associated with an increased risk of longer hospital stay and composite MACE during hospitalization of patients undergoing PCI. We should pay attention to COPD in patients undergoing PCI because they may need closer follow-up and targeted therapeutic interventions. Increasing severity of COPD was associated with adverse outcomes. Therefore, PFTs are useful for patients with COPD who undergo PCI.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-0003319712458145">
<label>Declaration of Conflicting Interests</label>
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0003319712458145">
<label>Funding</label>
<p>The author(s) received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0003319712458145">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hole</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Watt</surname>
<given-names>GC</given-names>
</name>
<name>
<surname>Davey-Smith</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Hart</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Gillis</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Hawthorne</surname>
<given-names>VM</given-names>
</name>
</person-group>. <article-title>Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study</article-title>. <source>BMJ</source>. <year>1996</year>;<volume>313</volume>:<fpage>711</fpage>–<lpage>715</lpage>.</citation>
</ref>
<ref id="bibr2-0003319712458145">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Falk</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Kadiev</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Criner</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Scharf</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Minai</surname>
<given-names>OA</given-names>
</name>
<name>
<surname>Diaz</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Cardiac disease in chronic obstructive pulmonary disease</article-title>. <source>Proc Am Thorac Soc</source>. <year>2008</year>;<volume>5</volume>(<issue>4</issue>):<fpage>543</fpage>–<lpage>548</lpage>.</citation>
</ref>
<ref id="bibr3-0003319712458145">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Engström</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Hedblad</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Valind</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Janzon</surname>
<given-names>L</given-names>
</name>
</person-group>. <article-title>Asymptomatic leg and carotid atherosclerosis in smokers is related to degree of ventilatory capacity: longitudinal and cross-sectional results from ‘Men born in 1914’, Sweden</article-title>. <source>Atherosclerosis</source>. <year>2001</year>;<volume>155</volume>(<issue>1</issue>):<fpage>237</fpage>–<lpage>243</lpage>.</citation>
</ref>
<ref id="bibr4-0003319712458145">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Engström</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Lind</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hedblad</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>Lung function and cardiovascular risk: relationship with inflammation-sensitive plasma proteins</article-title>. <source>Circulation</source>. <year>2002</year>;<volume>106</volume>(<issue>20</issue>):<fpage>2555</fpage>–<lpage>2560</lpage>.</citation>
</ref>
<ref id="bibr5-0003319712458145">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Filsoufi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Rahmanian</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Castillo</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Chikwe</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kini</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>DH</given-names>
</name>
</person-group>. <article-title>Results and predictors of early and late outcome of coronary artery bypass grafting in patients with severely depressed left ventricular function</article-title>. <source>Ann Thorac Surg</source>. <year>2007</year>;<volume>84</volume> (<issue>3</issue>):<fpage>808</fpage>–<lpage>816</lpage>.</citation>
</ref>
<ref id="bibr6-0003319712458145">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nishiyama</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Morimoto</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Furukawa</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Chronic obstructive pulmonary disease—an independent risk factor for long-term cardiac and cardiovascular mortality in patients with ischemic heart disease</article-title>. <source>Int J Cardiol</source>. <year>2010</year>;<volume>143</volume>(<issue>2</issue>):<fpage>178</fpage>–<lpage>183</lpage>.</citation>
</ref>
<ref id="bibr7-0003319712458145">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Samuels</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Kaufman</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Promisloff</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Brockman</surname>
<given-names>SK</given-names>
</name>
</person-group>. <article-title>Coronary artery bypass grafting in patients with COPD</article-title>. <source>Chest</source>. <year>1998</year>;<volume>113</volume>(<issue>4</issue>):<fpage>878</fpage>–<lpage>882</lpage>.</citation>
</ref>
<ref id="bibr8-0003319712458145">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pauwels</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Buist</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Calverley</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Jenkins</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Hurd</surname>
<given-names>SS</given-names>
</name>
</person-group>, <collab collab-type="author">GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease</collab>. <article-title>NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary</article-title>. <source>Am J Respir Crit Care Med</source>. <year>2001</year>;<volume>163</volume>(<issue>5</issue>):<fpage>1256</fpage>–<lpage>1276</lpage>.</citation>
</ref>
<ref id="bibr9-0003319712458145">
<label>9</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Morcos</surname>
<given-names>SK.</given-names>
</name>
</person-group> <article-title>Contrast medium-induced nephrotoxicity</article-title>. In: <person-group person-group-type="editor">
<name>
<surname>Dawson</surname>
<given-names>P</given-names>
</name>
</person-group>, ed. <source>Textbook of Contrast Media</source>. <publisher-name>Oxford, UK: Isis Medical Media Ltd</publisher-name>; <year>1999</year>.</citation>
</ref>
<ref id="bibr10-0003319712458145">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morcos</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Thomsen</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Webb</surname>
<given-names>JA</given-names>
</name>
</person-group>. <article-title>Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR)</article-title>. <source>Eur Radiol</source>. <year>1999</year>;<volume>9</volume>(<issue>8</issue>):<fpage>1602</fpage>–<lpage>1613</lpage>.</citation>
</ref>
<ref id="bibr11-0003319712458145">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rabe</surname>
<given-names>KF</given-names>
</name>
<name>
<surname>Hurd</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Anzueto</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary</article-title>. <source>Am J Respir Crit Care Med</source>. <year>2007</year>;<volume>176</volume>(<issue>6</issue>):<fpage>532</fpage>–<lpage>55</lpage>.</citation>
</ref>
<ref id="bibr12-0003319712458145">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuller</surname>
<given-names>LH</given-names>
</name>
<name>
<surname>Ockene</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Townsend</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Browner</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Meilahn</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Wentworth</surname>
<given-names>DN</given-names>
</name>
</person-group>. <article-title>The epidemiology of pulmonary function and COPD mortality in the multiple risk factor intervention trial</article-title>. <source>Am Rev Respir Dis</source>. <year>1989</year>;<volume>140</volume>(<issue>3 Pt 2</issue>):<fpage>S76</fpage>–<lpage>S78</lpage>.</citation>
</ref>
<ref id="bibr13-0003319712458145">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Selvaraj</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Gurm</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ellis</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Bhatt</surname>
<given-names>DL</given-names>
</name>
</person-group>. <article-title>Chronic obstructive pulmonary disease as a predictor of mortality in patients undergoing percutaneous coronary intervention</article-title>. <source>Am J Cardiol</source>. <year>2005</year>;<volume>96</volume>(<issue>6</issue>):<fpage>756</fpage>–<lpage>759</lpage>.</citation>
</ref>
<ref id="bibr14-0003319712458145">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berger</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Sanborn</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Sherman</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>DL</given-names>
</name>
</person-group>. <article-title>Effect of chronic obstructive pulmonary disease on survival of patients with coronary heart disease having percutaneous coronary intervention</article-title>. <source>Am J Cardiol</source>. <year>2004</year>;<volume>94</volume>(<issue>5</issue>):<fpage>649</fpage>–<lpage>651</lpage>.</citation>
</ref>
<ref id="bibr15-0003319712458145">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Konecny</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Somers</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Orban</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Interactions between COPD and outcomes after percutaneous coronary intervention</article-title>. <source>Chest</source>. <year>2010</year>;<volume>138</volume>(<issue>3</issue>):<fpage>621</fpage>–<lpage>627</lpage>.</citation>
</ref>
<ref id="bibr16-0003319712458145">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dev</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wallace</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sankaran</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Value of C-reactive protein measurements in exacerbations of chronic obstructive pulmonary disease</article-title>. <source>Respir Med</source>. <year>1998</year>;<volume>92</volume>(<issue>4</issue>):<fpage>664</fpage>–<lpage>667</lpage>.</citation>
</ref>
<ref id="bibr17-0003319712458145">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Andreas</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Anker</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Scanlon</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Somers</surname>
<given-names>VK</given-names>
</name>
</person-group>. <article-title>Neurohumoral activation as a link to manifestations of chronic lung disease</article-title>. <source>Chest</source>. <year>2005</year>;<volume>128</volume>(<issue>5</issue>):<fpage>3618</fpage>–<lpage>3624</lpage>.</citation>
</ref>
<ref id="bibr18-0003319712458145">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heindl</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lehnert</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Criée</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Hasenfuss</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Andreas</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Marked sympathetic activation in patients with chronic respiratory failure</article-title>. <source>Am J Respir Crit Care Med</source>. <year>2001</year>;<volume>164</volume>(<issue>4</issue>):<fpage>597</fpage>–<lpage>601</lpage>.</citation>
</ref>
<ref id="bibr19-0003319712458145">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hjalmarsen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Aasebø</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Aleksandersen</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Jorde</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Cardiovascular responses to tests for autonomic dysfunction in patients with chronic obstructive pulmonary disease with and without continuous long-term oxygen therapy</article-title>. <source>J Auton Nerv Syst</source>. <year>1996</year>;<volume>60</volume>(<issue>3</issue>):<fpage>169</fpage>–<lpage>174</lpage>.</citation>
</ref>
<ref id="bibr20-0003319712458145">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patakas</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Louridas</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kakavelas</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>Reduced baroreceptor sensitivity in patients with chronic obstructive pulmonary disease</article-title>. <source>Thorax</source>. <year>1982</year>;<volume>37</volume>(<issue>4</issue>):<fpage>292</fpage>–<lpage>295</lpage>.</citation>
</ref>
<ref id="bibr21-0003319712458145">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Collop</surname>
<given-names>N</given-names>
</name>
</person-group>. <article-title>Sleep and sleep disorders in chronic obstructive pulmonary disease</article-title>. <source>Respiration</source>. <year>2010</year>;<volume>80</volume>(<issue>1</issue>):<fpage>78</fpage>–<lpage>86</lpage>.</citation>
</ref>
<ref id="bibr22-0003319712458145">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kostapanos</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Elisaf</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Mikhailidis</surname>
<given-names>DP</given-names>
</name>
</person-group>. <article-title>Obstructive Sleep Apnea and Cardiovascular Risk: Is Metabolic Syndrome the Link? [published online February 8, 2012]</article-title>. <source>Angiology</source>. <year>2012</year>. doi:10.1177/0003319711436077</citation>
</ref>
<ref id="bibr23-0003319712458145">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barr</surname>
<given-names>RG</given-names>
</name>
<name>
<surname>Mesia-Vela</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Austin</surname>
<given-names>JH</given-names>
</name>
<etal/>
</person-group>. <article-title>Impaired flow mediated dilation is associated with low pulmonary function and emphysema in ex-smokers: the Emphysema and Cancer Action Project (EMCAP) Study</article-title>. <source>Am J Respir Crit Care Med</source>. <year>2007</year>;<volume>176</volume>(<issue>12</issue>):<fpage>1200</fpage>–<lpage>1207</lpage>.</citation>
</ref>
<ref id="bibr24-0003319712458145">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McAllister</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Maclay</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Mills</surname>
<given-names>NL</given-names>
</name>
<etal/>
</person-group>. <article-title>Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease</article-title>. <source>Am J Respir Crit Care Med</source>. <year>2007</year>;<volume>176</volume>(<issue>12</issue>):<fpage>1208</fpage>–<lpage>1214</lpage>.</citation>
</ref>
<ref id="bibr25-0003319712458145">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zarubina</surname>
<given-names>EG</given-names>
</name>
<name>
<surname>Mishina</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Osadchuk</surname>
<given-names>MA</given-names>
</name>
</person-group>. <article-title>The role of endothelial dysfunction in the pathogenesis of combined cardiopulmonary diseases</article-title>. <source>Klin Med (Mosk)</source>. <year>2006</year>;<volume>84</volume>(<issue>5</issue>):<fpage>31</fpage>–<lpage>34</lpage>.</citation>
</ref>
<ref id="bibr26-0003319712458145">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>BH</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Chronic obstructive pulmonary disease and metabolic syndrome: a nationwide survey in Korea</article-title>. <source>Int J Tuberc Lung Dis</source>. <year>2012</year>;<volume>16</volume>(<issue>5</issue>):<fpage>694</fpage>–<lpage>700</lpage>.</citation>
</ref>
<ref id="bibr27-0003319712458145">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marquis</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Maltais</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Duguay</surname>
<given-names>V</given-names>
</name>
<etal/>
</person-group>. <article-title>The metabolic syndrome in patients withchronic obstructive pulmonary disease</article-title>. <source>J Cardiopulm Rehabil</source>. <year>2005</year>;<volume>25</volume>(<issue>4</issue>):<fpage>226</fpage>–<lpage>232</lpage>. <comment>discussion 233-234</comment>.</citation>
</ref>
<ref id="bibr28-0003319712458145">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wakabayashi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Gonzalez</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Delhaye</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Impact of chronic obstructive pulmonary disease on acute-phase outcome of myocardial infarction</article-title>. <source>Am J Cardiol</source>. <year>2010</year>;<volume>106</volume>(<issue>3</issue>):<fpage>305</fpage>–<lpage>309</lpage>.</citation>
</ref>
<ref id="bibr29-0003319712458145">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Macnee</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Maclay</surname>
<given-names>J</given-names>
</name>
<name>
<surname>McAllister</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>Cardiovascular injury and repair in chronic obstructive pulmonary disease</article-title>. <source>Proc Am Thorac Soc</source>. <year>2008</year>;<volume>5</volume>(<issue>8</issue>):<fpage>824</fpage>–<lpage>833</lpage>.</citation>
</ref>
<ref id="bibr30-0003319712458145">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Curkendall</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>DeLuise</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>JK</given-names>
</name>
<etal/>
</person-group>. <article-title>Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients</article-title>. <source>Ann Epidemiol</source>. <year>2006</year>;<volume>16</volume>(<issue>1</issue>):<fpage>63</fpage>–<lpage>70</lpage>.</citation>
</ref>
<ref id="bibr31-0003319712458145">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karha</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bavry</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Rajagopal</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Henderson</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Ellis</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Brener</surname>
<given-names>SJ</given-names>
</name>
</person-group>. <article-title>Relation of C-reactive protein level and long-term risk of death or myocardial infarction following percutaneous coronary intervention with a sirolimus-eluting stent</article-title>. <source>Am J Cardiol</source>. <year>2006</year>;<volume>98</volume>(<issue>5</issue>):<fpage>616</fpage>–<lpage>618</lpage>.</citation>
</ref>
<ref id="bibr32-0003319712458145">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jurewitz</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Pessegueiro</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zimmer</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bhatia</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Tobis</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>MS</given-names>
</name>
</person-group>. <article-title>Preprocedural white blood cell count as a predictor of death and major adverse cardiac events in patients undergoing percutaneous coronary intervention with drug-eluting stents</article-title>. <source>J Invasive Cardiol</source>. <year>2009</year>;<volume>21</volume>(<issue>5</issue>):<fpage>202</fpage>–<lpage>206</lpage>.</citation>
</ref>
<ref id="bibr33-0003319712458145">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bertomeu</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Cordero</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Quiles</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mazon</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Aznar</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bueno</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Control of risk factors in and treatment of patients with coronary heart disease: the TRECE study</article-title>. <source>Rev Esp Cardiol</source>. <year>2009</year>;<volume>62</volume>(<issue>7</issue>):<fpage>807</fpage>–<lpage>811</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>